目的:比较伏诺拉生和奥美拉唑在治疗胃食管反流病方面的临床疗效。方法:在2023年1月到2023年12月的时间段内,选取在荣成市人民医院治疗的84名胃食管反流病患者,随机分为观察组42人选用伏诺拉生片进行治疗,对照组42人选用奥美拉唑肠溶胶...目的:比较伏诺拉生和奥美拉唑在治疗胃食管反流病方面的临床疗效。方法:在2023年1月到2023年12月的时间段内,选取在荣成市人民医院治疗的84名胃食管反流病患者,随机分为观察组42人选用伏诺拉生片进行治疗,对照组42人选用奥美拉唑肠溶胶囊进行治疗,随后对两组的治疗效果进行了对比分析。结果:观察组的治疗总有效率明显高于对照组(95.24% vs. 85.71%, P P均 P χ2 = 0.091, P = 0.763)。结论:伏诺拉生片对胃食管反流病有较好的临床疗效,在改善患者生活质量的同时,能减轻患者的症状,降低炎症因子水平,安全性较好。Objective: To compare the clinical efficacy of vonoprazan and omeprazole in the treatment of gastroesophageal reflux disease. Methods: During the period from January 2023 to December 2023, 84 patients with gastroesophageal reflux disease treated in Rongcheng People’s Hospital were selected, 42 patients in the observation group were selected with vonoprazan tablets for treatment, and 42 patients in the control group chose omeprazole enteric capsules for treatment. Subsequently, the treatment effect of the two groups was compared. Results: The overall response rate in the observation group was significantly higher than that in the control group (95.24% vs. 85.71%, P P P 2 = 0.091, P = 0.763). Conclusion: Vonoprazan has a good clinical effect on gastroesophageal reflux disease, can reduce the symptoms of patients, improve the quality of life of patients, reduce the level of inflammatory factors, and the safety is good.展开更多
文摘目的:比较伏诺拉生和奥美拉唑在治疗胃食管反流病方面的临床疗效。方法:在2023年1月到2023年12月的时间段内,选取在荣成市人民医院治疗的84名胃食管反流病患者,随机分为观察组42人选用伏诺拉生片进行治疗,对照组42人选用奥美拉唑肠溶胶囊进行治疗,随后对两组的治疗效果进行了对比分析。结果:观察组的治疗总有效率明显高于对照组(95.24% vs. 85.71%, P P均 P χ2 = 0.091, P = 0.763)。结论:伏诺拉生片对胃食管反流病有较好的临床疗效,在改善患者生活质量的同时,能减轻患者的症状,降低炎症因子水平,安全性较好。Objective: To compare the clinical efficacy of vonoprazan and omeprazole in the treatment of gastroesophageal reflux disease. Methods: During the period from January 2023 to December 2023, 84 patients with gastroesophageal reflux disease treated in Rongcheng People’s Hospital were selected, 42 patients in the observation group were selected with vonoprazan tablets for treatment, and 42 patients in the control group chose omeprazole enteric capsules for treatment. Subsequently, the treatment effect of the two groups was compared. Results: The overall response rate in the observation group was significantly higher than that in the control group (95.24% vs. 85.71%, P P P 2 = 0.091, P = 0.763). Conclusion: Vonoprazan has a good clinical effect on gastroesophageal reflux disease, can reduce the symptoms of patients, improve the quality of life of patients, reduce the level of inflammatory factors, and the safety is good.
